TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01193530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy
Description: 30 minutes every day for 14 days. After enrollment on day 0, blinded phase of study intervention (i.e. daily bright light or red light) from day 1 to day 14+/-3, then proceed to the open label phase and receive daily bright light between day 15+/-3 and day 28+/-3.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dim Red Light Therapy
Description: From day 1 to day 14+/-3, daily dim red light therapy for 30 minutes for 14 days where red light device accounts for placebo of the blinded phase of study intervention, then between day 15+/-3 and day 28+/-3 open label phase with daily bright light.
Study: NCT00411788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: oral rapamycin 6 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 4 mg/kg will be administered (intravenous) on day 1, and this will be followed by weekly dose of 2 mg/kg starting day 8.
Study: NCT00376597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive lymphedema educational materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive lymphedema educational materials

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Complete physical therapy-focused intervention
Study: NCT00695591

Intervention type: OTHER
Intervention: Evaluation for Nocturnal non invasive ventilation
Description: Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 \>6.0 Pa; and 2) nocturnal Sa,O2 \<88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV

Intervention type: OTHER
Intervention: Evaluation for Nocturnal non invasive ventilation
Description: Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 \>6.0 Pa; and 2) nocturnal Sa,O2 \<88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV

Intervention type: OTHER
Intervention: Evaluation for Nocturnal non invasive ventilation
Description: Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 \>6.0 Pa; and 2) nocturnal Sa,O2 \<88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV

Intervention type: OTHER
Intervention: Evaluation for Nocturnal non invasive ventilation
Description: Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 \>6.0 Pa; and 2) nocturnal Sa,O2 \<88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV
Study: NCT01193530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Weekly

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Weekly

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Diaries
Description: Daily logs

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Study Diaries
Description: Daily logs

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Red Light Litebook
Description: Control red light device produced by Litebook identical in appearance and dimensions to the bright light device, with the exception it emits at wavelength 680nm (i.e. red light) and at an intensity of 50 lux.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright Light Litebook
Description: Bright light device consists of 60 LEDs with spectral emission peak at approximately 464nm and fluorescent phosphors which provide a broader, secondary spectral peak near 564nm. Collectively the emitted light appears white.
Study: NCT01544283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch
Description: Synera consists of a thin, uniform layer of a local anesthetic formulation with an integrated, oxygen-activated heating component that is intended to enhance the delivery of the local anesthetics. The drug formulation is an emulsion in which the oil phase is a eutectic mixture of lidocaine 70 mg and tetracaine 70 mg. The surface area of the entire Synera patch is approximately 50 cm2, 10 cm2 of which is active. The 40 cm2 perimeter is a medical grade adhesive. The Synera patches used in this study are the commercially available form.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Triamcinolone Acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intralesional and intra-articular injection. Each mL of the sterile aqueous suspension provides 40 mg of triamcinolone acetonide, with sodium chloride for isotonicity, 0.9% (w/v) benzyl alcohol as a preservative, 0.75% carboxymethylcellulose sodium, and a 0.04% polysorbate 80; sodium hydroxide or hydrochloric acid may have been added to adjust pH between 5.0 and 7.5. At the time of manufacture, the air in the container is replaced by nitrogen.
Study: NCT00992290

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Description: 1 capsule of lactobacillus GG BID compared to placebo BID

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule of lactobacillus GG BID compared to placebo BID
Study: NCT00094172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: atorvastatin at the dose of 80 mg/day. Participants will be allowed to decrease the daily dose to 40 mg/day if the higher dose is not well-tolerated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet form
Study: NCT01842321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Patients will receive abiraterone acetate at 1,000 mg (four 250 mg tablets daily in the morning after an overnight fast) concurrently with prednisone(1) at 10 mg once daily.
Study: NCT01164800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trandolapril
Description: Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mavik
Description: Mavik® 4 mg Tablets of Abbott Laboratories, USA.
Study: NCT03120000

Intervention type: DRUG
Group type: OTHER
Intervention: PQR309
Description: Oral PQR309, 80mg or 60mg daily or intermittent dosing
Study: NCT04188847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus apatinib
Description: A combination of cisplatin, paclitaxel and apatinib would be given for all patients:~* Cisplatin: 50 mg/m2 body surface area, on the first day, every 3 weeks. If the creatinine clearance rate was less than 40 ml/min, the cisplatin would be replace by carboplatin (area under ther curve = 5)~* Paclitaxel: 50 mg/m2 body surface area, on the first day, every 3 weeks~* Apatinib: 250 mg every day The total courses of cisplatin and paclitaxel would be no more than 6.
Study: NCT04198298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EndoSequence
Description: The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ProRoot MTA
Description: The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biodentine
Description: The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
Study: NCT00818597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EISS
Description: Two six hour-treatments with the EISS-Immune-cell bioreactor device within 72 hours post inclusion.
Study: NCT01582568

Intervention type: DRUG
Intervention: Certolizumab
Description: Certolizumab 200mg-400mg subcutaneous every 2 weeks for 8 weeks.
Study: NCT03169010

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Laboratory results will be analysed to identify disease related biomarkers.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Laboratory results will be analysed to identify disease related biomarkers.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Laboratory results will be analysed to identify disease related biomarkers.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Laboratory results will be analysed to identify disease related biomarkers.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Laboratory results will be analysed to identify disease related biomarkers.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Laboratory results will be analysed to identify disease related biomarkers.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Laboratory results will be analysed to identify disease related biomarkers.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Laboratory results will be analysed to identify disease related biomarkers.

Intervention type: GENETIC
Intervention: Genetic analysis
Description: Gene sequencing results will be analysed to identify disease related mutations.

Intervention type: GENETIC
Intervention: Genetic analysis
Description: Gene sequencing results will be analysed to identify disease related mutations.

Intervention type: GENETIC
Intervention: Genetic analysis
Description: Gene sequencing results will be analysed to identify disease related mutations.
Study: NCT00044083

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: One capsule 3 times a day from Day 1 to Day 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolcapone
Description: Tolcapone: One capsule 3 times a day from Day 1 to Day 7
Study: NCT01059591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK424887
Description: GSK424887 2mg, 10mg, 50mg, 100mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match GSK424887 2mg, 10mg,50mg, 100mg capsule

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET
Description: Each subject will undergo 3 PET scans : one at Baseline and the others following dosing with GSK424887 at approximately 2h post-dose and aproximately 24 hours post-dose
Study: NCT01878279

Intervention type: OTHER
Intervention: Underlying medical illness
Study: NCT04609371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-care tools
Description: self-care tools only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-care tools
Description: self-care tools only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lay telephone coaching
Description: coaching
Study: NCT03841812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5mg/kg/h Propofol
Description: 5mg/kg/h Propofol continuously infused during intre-operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 1% Sevoflurane continuously using during intre-operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg/kg/h Propofol
Description: 2mg/kg/h Propofol continuously infused during intre-operation
Study: NCT05318950

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet
Description: Diet A: MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids) Diet B: MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids)
Study: NCT04179227

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT01685892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive IV infusion of obinutuzumab 100 milligrams (mg) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive IV infusion of obinutuzumab 100 milligrams (mg) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
Study: NCT01762072

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Study: NCT01685892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive IV infusion of obinutuzumab 100 milligrams (mg) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive IV infusion of obinutuzumab 100 milligrams (mg) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive IV infusion of obinutuzumab 100 milligrams (mg) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive IV infusion of obinutuzumab 100 milligrams (mg) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive multiple doses of venetoclax orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive multiple doses of venetoclax orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive multiple doses of venetoclax orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive multiple doses of venetoclax orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive multiple doses of venetoclax orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive multiple doses of venetoclax orally once daily.
Study: NCT00763711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle Guided Periurethral Injection
Description: Bulking Agent injection using a needle guide
Study: NCT01484223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Four Cognitive behavioral group sessions. Each session will last two hours a week
Study: NCT02179866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5285119
Description: Single oral dose of RO5285119 with approximately 2.1 MBq (56.6 uCi) \[14C\]-radiolabeled RO5285119 administered as a drinking solution under fasted conditions on Day -1
Study: NCT01519232

Intervention type: RADIATION
Intervention: Liver Irradiation
Description: Patients already scheduled to undergo radiation treatment
Study: NCT03998930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical evaluation of consciousness by the Coma Recovery Scale Revised (CRS-R)
Description: Paraclinical evaluation of consciousness by the brain-machine interface by measuring evoked potentials P300 auditory and vibrotactile and recording the EEG signal during a motor imaging task
Study: NCT04312750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8%
Study: NCT03391089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BBL Experimental Navigation System
Description: Comparison of accuracy of screw placement using experimental system.
Study: NCT05820945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review
Description: Clinical review by a primary care pharmacist of the primary care clinical history and the pharmacological treatment plan. After the review process, a meeting will be held between the pharmacist and the responsible physician in order to present proposals for pharmacotherapeutic optimization.
Study: NCT03026322

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Ventilation
Description: Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Manual Ventilation
Description: Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
Study: NCT04452682

Intervention type: OTHER
Intervention: COVID 19 impact
Description: The impact of COVID-19 pandemic on Critical limb threatening ischemia and emergency vascular practice
Study: NCT04360668

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Energy Technique (MET)
Description: The Contract-Relax Agonist-Contract (CRAC) technique will be used, which belongs to the broad MET group. The participant will be in the supine position. The therapist will set the cervical segment in the lateral flexion until a slight soft tissue tension is felt. The technique will consist of two stages. In the first phase (contraction phase), the upper trapezius will be activated against the therapist's resistance (shoulder girdle elevation) - 10 seconds. Then the person undergoing the procedure breathes in and out deeply. Then 10 seconds of antagonist group contraction (shoulder girdle depression) will be performed. Next, the therapist will passively move the participant's shoulder girdle towards the depression. Then the second phase will follow (stretching phase), during which the participant will passively lie in the back position for 30 seconds. Both phases will make up the therapeutic cycle. Each participant will have 5 cycles on each side of the upper trapezius.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trigger Point Therapy (TPT)
Description: The technique of Positional Release (PR) will be used, which is one of the broadly understood Trigger Point Therapy. It will consist in compressing the trigger point with a simultaneous shortening of muscle attachments (slight lateral flexion towards the relaxed muscle). The muscle on both sides will be treated. The pressure exerted by the therapist's pincer grip will be acceptable to the patient. The duration of the technique will be 2 minutes for each muscle. While performing this technique, the participant will passively lie on his back.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique (MET) combined with Trigger Point Therapy (TPT)
Description: For this type of intervention, TPT will first be performed on both sides of the upper trapezius muscle, followed by MET, which will also be performed bilaterally. The detailed method of performing the applied therapeutic techniques for the combined procedure will be identical as in the case of isolated (single) methods.
Study: NCT02747875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
Study: NCT03019783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: The active group will switch from a non-atazanavir regimen to an atazanavir-based regimen.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will stay on their baseline regimen
Study: NCT03760978

Intervention type: DRUG
Intervention: Dexmedetomidine
Study: NCT04715633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor plus VEGF inhibitors
Description: Camrelizumab 200mg IV every 3 weeks; Apatinib 250mg QD day 1-14. Rescue chemotherapy: Oxaliplatin 130mg/m2 IV drip Q3W d1+Capecitabine 1000mg/m2 QD d1-d14 Rescue chemoradiotherapy: Long-course radiotherapy +Capecitabine 825mg/m2 QD d1-d14
Study: NCT01762072

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitaminB12

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitaminB12
Study: NCT02377505

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On-Stimulation
Description: The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is on

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Off-Stimulation
Description: The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is off